The bill would require the Director of the Bureau of Prisons to ensure an adequate number of opioid antagonist kits at each federal correctional facility, with kits placed in medical housing units, staff breakrooms, visiting areas, and other common spaces to ensure rapid access. It also requires proper storage conditions and routine expiration checks, and mandates annual training for staff and incarcerated people on how to administer opioid antagonists and recognize overdoses.
In addition, the bill requires documentation of every administration, shield of liability for good-faith actions, and annual reporting to Congress on stock, overdoses, trainings, and expired kits, supported by new appropriations to implement the program.
At a Glance
What It Does
Adds Section 4052 to Title 18 to require federal facilities to maintain an adequate supply of opioid antagonist kits, store them properly, and ensure access in key locations. It also requires annual training, administration documentation, liability protections, and annual reporting.
Who It Affects
Federal Bureau of Prisons facilities, correctional staff, medical personnel, and incarcerated individuals who may witness or require overdose intervention.
Why It Matters
Establishes a federal standard for overdose response in prisons, improves safety, and provides data to evaluate program effectiveness and budget needs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Federal Prisons Naloxone Access Act of 2025 would obligate the Bureau of Prisons (BOP) to ensure opioid antagonists (such as naloxone) are available at every federal correctional facility. The bill requires maintaining an adequate number of antidote kits and placing them in locations where overdoses could occur or be observed, including medical housing units, staff areas, and common spaces.
Kits must be stored under appropriate conditions (room temperature, out of direct sunlight) and in secure areas accessible to facility personnel. Incarcerated people would be allowed to access these kits to help someone experiencing an overdose, with liability protections for those administering the antidote in good faith.
The Five Things You Need to Know
The bill adds Section 4052 to require availability and placement of opioid antagonist kits at all federal facilities.
Kits must be stored properly (room temperature, away from sunlight) and kept in secure, accessible areas.
Inmates and staff can administer the antagonist to overdoses, with liability protections for good-faith actions.
Each administration must be documented with location, time, recipient, and administrator details.
The bill authorizes initial and ongoing funding ($6M in 2026; $2M in 2027–28) and requires annual Congress reporting on stock, overdoses, trainings, and expirations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Availability of opioid antagonist kits
The Director of the Bureau of Prisons must ensure an adequate number of opioid antagonist kits at each federal correctional facility and place these kits in key locations including medical housing units, staff breakrooms, visiting areas, living quarters, and other spaces where incarcerated individuals congregate. This provision directly ties kit accessibility to multiple touchpoints within the facility to maximize the chance of timely intervention during an overdose.
Expiration management
Each opioid antagonist kit must be regularly checked for expiration, and replacements must be made as needed. This ensures that every kit remains immediately usable and reduces the risk of non-functional antidotes during an overdose event.
Training requirements
The Director must ensure annual training for both facility personnel and incarcerated individuals on administering opioid antagonists and on recognizing signs of an opioid overdose. Training will be delivered by bureau medical staff and is intended to build competency across responders and non-clinical staff alike.
Documentation of administrations
For every administration of an opioid antagonist, facilities must document the location, time, recipient, the name and status of the administrator, and other relevant details. This creates a traceable record to support oversight, post-event analysis, and program evaluation.
Liability protections
Inmates who administer an opioid antagonist in good faith are shielded from liability. This provision is intended to reduce hesitation during emergencies and encourage timely intervention without legal fear.
Congressional reporting
The Director must submit an annual report detailing the quantity of antagonists available at each facility, the number of overdoses, training counts, and the number of expired kits. The report provides a program-wide view of implementation and effectiveness.
Definitions
Key terms are defined: an opioid antagonist is an FDA-approved medication that neutralizes opioids; an opioid overdose prevention kit combines an antagonist with guidance materials; and personnel include correctional officers, medical staff, counselors, and other Bureau employees.
Appropriations
The bill authorizes funding to support implementation: $6,000,000 for FY2026 for training, purchase of antagonists, and the initial report; and $2,000,000 for FY2027 and FY2028 for maintenance, training, and ongoing reporting on effectiveness.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Incarcerated individuals at risk of overdose or who may witness an overdose, who gain timely access to reversal medication.
- Correctional medical staff responsible for overdose response and clinical care.
- Correctional officers who may be first responders in medical emergencies.
- Facility administrators seeking to enhance safety and compliance with federal standards.
- Public health and Congress tracking overdose prevention outcomes and program efficacy.
Who Bears the Cost
- Federal taxpayers funding the acquisition of opioid antagonists and related training.
- BOP facilities bearing ongoing costs for storage, stocking, and management of kits.
- Suppliers and manufacturers of opioid antagonist kits providing reagents and equipment.
- Facility staff time and security resources dedicated to training and documentation.
Key Issues
The Core Tension
The central dilemma is balancing rapid, universal access to overdose reversal against the costs, logistics, and security considerations of administering and maintaining kits across diverse facilities.
The bill creates a federal standard for overdose response in prisons, but it also raises practical questions about implementation at scale. Stocking and maintaining kits across all locations, ensuring consistent access in every facility, and sustaining annual training require ongoing funding and management.
Data collection on overdoses and kit expiration will inform future budgeting, but the program’s success depends on reliable reporting and continuity despite turnover in staff or facility conditions. The liability shield for good-faith actions reduces legal risk but does not address potential medical or operational ambiguities that could arise during high-stress overdose events.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.